Apollo Endosurgery, Inc. Announces Pricing of $31 Million Public Offering

B2B Training: What’s the Most Effective Way of Learning?

B2B training, which is short for business-to-business training, is a popular and convenient type of training that enables entire companies to train their teams...

AlixPartners Forecasts: Household Products Could Cost U.S. Manufacturers and Consumers 15% More This Year Due to Resin Shortage

While companies can’t control the market forces at play, they can take action to mitigate the risk and impact of supply chain disruption.

Apollo Endosurgery, Inc. (NASDAQ: APEN), a medical technology company primarily focused on the design, development and commercialization of innovative medical devices that can be used for the treatment of obesity, today announced the pricing of an underwritten public offering of 5,689,090 shares of its common stock at a public offering price of $5.50 per share, before underwriting discounts and commissions. All of the common stock is being offered by Apollo. In addition, Apollo has also granted the underwriters a 45-day option to purchase up to an additional 853,363 shares of common stock. The offering is expected to close on July 25, 2017, subject to customary closing conditions.

Craig-Hallum Capital Group LLC and Roth Capital Partners are acting as joint book-running managers for the offering.

A registration statement relating to these securities was declared effective by the Securities and Exchange Commission (the “SEC”) on July 19, 2017. The offering is being made only by means of a prospectus forming part of the effective registration statement. A preliminary prospectus related to the offering has been filed with the SEC and is available on the SEC’s website, located at www.sec.gov. When available, copies of the final prospectus relating to the offering may be obtained from Craig-Hallum Capital Group LLC at 222 South Ninth Street, Suite 350, Minneapolis, Minnesota 55402, Attention: Equity Capital Markets, by telephone at 612-334-6300, or by e-mail at prospectus@chlm.com, or alternatively from Roth Capital Partners, LLC, Attention: Equity Capital Markets, 888 San Clemente Drive, Newport Beach, CA 92660, by telephone at 800-678-9147, or by email at rothecm@roth.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or other jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.

spot_img

DON'T MISS

Mediclinic Appoints 2 New Independent Non-Executive Directors

Natalia Barsegiyan and Zarina Bassa will bring significant and diverse skills and experience, complementing those of existing Board members. I am confident they will both be great additions to our Board of Directors.”

Asensus Surgical Appoints Two New Board Members

Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today announced the expansion of its Board of Directors, appointing...

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.